Exact Mass: 315.036704312
Exact Mass Matches: 315.036704312
Found 193 metabolites which its exact mass value is equals to given mass value 315.036704312,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Chlorprothixene
C18H18ClNS (315.08484180000005)
Chlorprothixene is only found in individuals that have used or taken this drug. It is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. Chlorprothixene blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AF - Thioxanthene derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Chlorprothixene is a dopamine and histamine receptors antagonist with Kis of 18 nM, 2.96 nM, 4.56 nM, 9 nM and 3.75 nM for hD1, hD2, hD3, hD5 and hH1 receptors, respectively. Antipsychotic activity[1].
Efavirenz
Efavirenz (brand names Sustiva and Stocrin) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065688 - Cytochrome P-450 CYP2C9 Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D065693 - Cytochrome P-450 Enzyme Inducers > D065695 - Cytochrome P-450 CYP2B6 Inducers D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3292 CONFIDENCE standard compound; INTERNAL_ID 8518
Oxfendazole
C15H13N3O3S (315.06775880000004)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3672; ORIGINAL_PRECURSOR_SCAN_NO 3670 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3663; ORIGINAL_PRECURSOR_SCAN_NO 3660 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3677; ORIGINAL_PRECURSOR_SCAN_NO 3673 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3666; ORIGINAL_PRECURSOR_SCAN_NO 3662 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3739; ORIGINAL_PRECURSOR_SCAN_NO 3736 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3676; ORIGINAL_PRECURSOR_SCAN_NO 3674 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7569; ORIGINAL_PRECURSOR_SCAN_NO 7565 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7593; ORIGINAL_PRECURSOR_SCAN_NO 7591 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7621; ORIGINAL_PRECURSOR_SCAN_NO 7619 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7615; ORIGINAL_PRECURSOR_SCAN_NO 7613 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7596; ORIGINAL_PRECURSOR_SCAN_NO 7593 CONFIDENCE standard compound; INTERNAL_ID 438; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 7629; ORIGINAL_PRECURSOR_SCAN_NO 7627 CONFIDENCE standard compound; INTERNAL_ID 1165 CONFIDENCE standard compound; INTERNAL_ID 1065
clonazepam
N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AE - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
Clonazepam
An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses. [PubChem] N - Nervous system > N03 - Antiepileptics > N03A - Antiepileptics > N03AE - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
Oxfendazole
C15H13N3O3S (315.06775880000004)
D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000871 - Anthelmintics C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent Anthelmintic, used in cattle, sheep and horse
Bromazepam
Bromazepam is only found in individuals that have used or taken this drug. It is one of the benzodiazepines that is used in the treatment of anxiety disorders. [PubChem] It is a Schedule IV drug in the U.S. and Canada and under the Convention on Psychotropic Substances.Bromazepam binds to the GABA receptor GABAA, causing a conformational change and increasing inhibitory effects of GABA. Other neurotransmitters are not influenced. D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
Avenanthramide C
Avenanthramide c is a member of the class of compounds known as avenanthramides. Avenanthramides are a group of phenolic alkaloids consisting of conjugate of three phenylpropanoids (ferulic, caffeic, or p-coumaric acid) and anthranilic acid. Avenanthramide c is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Avenanthramide c can be found in cereals and cereal products, which makes avenanthramide c a potential biomarker for the consumption of this food product. N-(3,4-Dihydroxycinnamoyl)-2-amino-5-hydroxybenzoic acid is found in cereals and cereal products. N-(3,4-Dihydroxycinnamoyl)-2-amino-5-hydroxybenzoic acid is isolated from oats (Avena sativa).
4-Nitrophenyl beta-D-glucopyranosiduronic acid
4-Hydroxyfenbendazole
C15H13N3O3S (315.06775880000004)
(7R)-5-Chloro-3-phenyl-7,8-dihydrofuro[2,3-g][1,2]benzoxazole-7-carboxylic acid
N-(3-Chlorophenyl)-6,7-dimethoxyquinazolin-4-amine
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D000970 - Antineoplastic Agents > D020032 - Tyrphostins D004791 - Enzyme Inhibitors
Midesteine
C12H13NO3S3 (315.00575480000003)
C78273 - Agent Affecting Respiratory System > C74536 - Mucolytic Agent
N-(3',4'-Dihydroxycinnamoyl)-5-hydroxyanthranilic acid
Phosphonate analog
C10H14N5O5P (315.07325240000006)
TrkA Inhibitor
C15H13N3O3S (315.06775880000004)
Avenanthramide K
Avenanthramide k is a member of the class of compounds known as avenanthramides. Avenanthramides are a group of phenolic alkaloids consisting of conjugate of three phenylpropanoids (ferulic, caffeic, or p-coumaric acid) and anthranilic acid. Avenanthramide k is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Avenanthramide k can be found in oat, which makes avenanthramide k a potential biomarker for the consumption of this food product.
AG-1478
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D000970 - Antineoplastic Agents > D020032 - Tyrphostins D004791 - Enzyme Inhibitors
Nicosulfuron-TP UCSN
C10H13N5O5S (315.0637368000001)
CONFIDENCE standard compound; UCHEM_ID 4212
methyl (-)-3S-8-bromo-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
methyl (-)-3S-6-bromo-8-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
S-(2-Amino-4-(4-methoxyphenyl)-1-methyl-1H-imidazol-5-yl) O-hydrogen sulfothioate
N-[4-(Dimethylarsinoyl)butanoyl]aminoethylsulfonic acid
bromazepam
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C29756 - Sedative and Hypnotic > C1012 - Benzodiazepine D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants D018377 - Neurotransmitter Agents > D018682 - GABA Agents > D018757 - GABA Modulators C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent CONFIDENCE standard compound; EAWAG_UCHEM_ID 3628 CONFIDENCE standard compound; INTERNAL_ID 1515
chlorprothixene
C18H18ClNS (315.08484180000005)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents N - Nervous system > N05 - Psycholeptics > N05A - Antipsychotics > N05AF - Thioxanthene derivatives D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C29710 - Antipsychotic Agent Chlorprothixene is a dopamine and histamine receptors antagonist with Kis of 18 nM, 2.96 nM, 4.56 nM, 9 nM and 3.75 nM for hD1, hD2, hD3, hD5 and hH1 receptors, respectively. Antipsychotic activity[1].
Efavirenz
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065689 - Cytochrome P-450 CYP2C19 Inhibitors D004791 - Enzyme Inhibitors > D065607 - Cytochrome P-450 Enzyme Inhibitors > D065688 - Cytochrome P-450 CYP2C9 Inhibitors D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors D065693 - Cytochrome P-450 Enzyme Inducers > D065695 - Cytochrome P-450 CYP2B6 Inducers D065693 - Cytochrome P-450 Enzyme Inducers > D065701 - Cytochrome P-450 CYP3A Inducers D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors C254 - Anti-Infective Agent > C281 - Antiviral Agent CONFIDENCE standard compound; INTERNAL_ID 2357
p-[N-Propyl-N-(2-carboxyethyl)sulfamoyl]benzoic acid
C13H17NO6S (315.07765420000004)
4-(4,5-DICHLORO-1H-IMIDAZOL-1-YL)-N-HYDROXY-3-NITROBENZENECARBOXIMIDAMIDE
Sulfamide,N-(6-hydroxy-4,5,7-trimethyl-2-benzothiazolyl)-N,N-dimethyl-
C12H17N3O3S2 (315.07112920000003)
3-[[2-(1,3-benzodioxol-5-yloxy)acetyl]amino]benzoic acid
Phenyl (4-chloro-3-(trifluoromethyl)phenyl)carbamate
4-chloro-6-(trifluoromethoxy)-2-(trifluoromethyl)quinoline
Methyl 3-bromo-4-[3-(dimethylamino)propoxy]benzoate
2-(3-BROMO-PHENYL)-N-(2,2-DIMETHOXY-ETHYL)-N-METHYL-ACETAMIDE
1-ETHANONE, 2-CHLORO-1-[2,5-DIMETHYL-1-[3-(TRIFLUOROMETHYL)PHENYL]-1H-PYRROL-3-YL]-
3-CHLORO-3-(CYCLOPROPYLCARBAMOYL)-[1,1-BIPHENYL]-4-CARBOXYLIC ACID
C17H14ClNO3 (315.06621640000003)
[4-(pyridin-3-ylmethyl)morpholin-2-yl]methanamine
C11H20Cl3N3O (315.06718800000004)
tert-Butyl (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate
7-Anilino-4-hydroxy-2-naphthalenesulfonic acid
C16H13NO4S (315.05652580000003)
Fotemustine
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01A - Alkylating agents > L01AD - Nitrosoureas C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C2842 - DNA Binding Agent D000970 - Antineoplastic Agents
(R)-(-)-n-(3,5-dinitrobenzoyl)-alpha-phenylethylamine
TERT-BUTYL 2-(CHLOROSULFONYL)-1H-INDOLE-1-CARBOXYLATE
C13H14ClNO4S (315.03320340000005)
3-[2-(4-Chlorophenoxy)phenyl]-1,5-dihydro-4-hydroxy-1-methyl-2H-pyrrol-2-one
C17H14ClNO3 (315.06621640000003)
2-(4-ACETOPHENOXY)-3-CHLORO-5-TRIFLUOROMETHYL PYRIDINE
2-[4-(2-pyrimidinyl)-1-piperazinyl]ethanamine(SALTDATA: 3HCl)
C10H20Cl3N5 (315.07842100000005)
7-Anilino-1-naphthol-3-sulfonic Acid
C16H13NO4S (315.05652580000003)
ETHYL 2-(4-CHLOROPHENYL)-7-METHYLPYRAZOLO[1,5-A]PYRIMIDINE-6-CARBOXYLATE
6-[Methyl(propyl)amino]-5,6,7,8-tetrahydro-2,3-naphthalenediol hy drobromide (1:1)
ethyl 4-chloro-5-methyl-7-phenylpyrrolo[2,3-d]pyrimidine-6-carboxylate
2-CYANO-2-(3-ETHYL-4-OXO-5-((PHENYLAMINO)METHYLENE)THIAZOLIDIN-2-YLIDENE)ACETIC ACID
C15H13N3O3S (315.06775880000004)
2,5-dimethyl-4-(2-thienylaminosulphonyl)furan-3-carboxylic acid
N-(p-Toluenesulfonyl)indole-3-boronic acid
C15H14BNO4S (315.07365540000006)
disodium,1-(N-benzylcarbamimidoyl)-2-phosphonatoguanidine,hydrate
5-METHYL-2-PHENYL-2,5-DIHYDRO-1H-PYRAZOL-3-YL 2-CHLORONICOTINATE
1-(benzenesulfonyl)indole-2-carbohydrazide
C15H13N3O3S (315.06775880000004)
4-Chloro-2-(piperazin-1-yl)-6-(trifluoromethyl)quinoline
5-[ISOCYANO-(TOLUENE-4-SULFONYL)-METHYL]-BENZO[1,3]DIOXOLE
C16H13NO4S (315.05652580000003)
(S)-(+)-CROTONYLCYCLOPENTANEDIENYLIRONCARBONYLTRIPHENYLPHOSPHINECOMPLEX
b-Alanine,N-(2-carboxyethyl)-N-[(4-methylphenyl)sulfonyl]-
C13H17NO6S (315.07765420000004)
ETHYL 2-(2-[3-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-4-YL)ACETATE
3-[4-[(4-METHYLPHENYL)THIO]-3-NITROPHENYL]ACRYLIC ACID
C16H13NO4S (315.05652580000003)
5-bromo-2-chloro-N-cyclohexylbenzamide
C13H15BrClNO (315.00254700000005)
2-(2-CHLORO-ACETYLAMINO)-5,6,7,8-TETRAHYDRO-4H-CYCLOHEPTA[B]THIOPHENE-3-CARBOXYLIC ACID ETHYL ESTER
3-[2-[(4-METHYLPHENYL)THIO]-5-NITROPHENYL]ACRYLIC ACID
C16H13NO4S (315.05652580000003)
p-Nitrophenyl-beta-D-glucuronide
(E)-1-TERT-BUTYL4-ETHYL2,3,6,7-TETRAHYDROAZEPINE-1,4-DICARBOXYLATE
7-chloro-8-methyl-2-phenyl-quinoline-4-carbonyl chloride
C17H11Cl2NO (315.02176560000004)
3-Amino-6-bromo-4-(pyridin-2-yl)quinolin-2(1H)-one
[4-(pyridin-2-ylmethyl)morpholin-2-yl]methanamine
C11H20Cl3N3O (315.06718800000004)
{[4-Benzyl-5-(2-furyl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid
C15H13N3O3S (315.06775880000004)
3-amino-4-(4-chloro-3,5-dimethylphenoxy)benzotrifluoride
2-(2-CHLORO-ACETYLAMINO)-6-METHYL-4,5,6,7-TETRAHYDRO-BENZO[B]THIOPHENE-3-CARBOXYLIC ACID ETHYL ESTER
3-(5-chloro-2-phenoxyphenyl)-1-methylpyrrolidine-2,4-dione
C17H14ClNO3 (315.06621640000003)
4-chloro-8-(trifluoromethoxy)-2-(trifluoromethyl)quinoline
Ethyl 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylate
Cidofovir Dihydrate
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C471 - Enzyme Inhibitor > C29575 - DNA Polymerase Inhibitor C254 - Anti-Infective Agent > C281 - Antiviral Agent D004791 - Enzyme Inhibitors
4-(4-fluorophenyl)-3-[2-(4-hydroxyphenyl)ethyl]-1H-1,2,4-triazole-5-thione
C16H14FN3OS (315.08415660000003)
ETHYL 4,6-DICHLORO-2-(METHYLTHIO)QUINOLINE-3-CARBOXYLATE
C13H11Cl2NO2S (314.98875260000005)
2,5-dichloro-N-(2-(diMethylphosphoryl)phenyl)pyriMidin-4-aMine
C12H12Cl2N3OP (315.00950120000005)
2,4-Dichloro-6-(dibenzo[b,d]furan-3-yl)-1,3,5-triazine
AZD-4635
AZD4635 (HTL1071) is a potent, selective and orally active adenosine A2A receptor (A2AR) antagonist. AZD4635 binds to human A2AR with a Ki of 1.7 nM and shows >30-fold selectivity over other adenosine receptors[1].
N-((2-methyl-5-nitrophenyl)carbamothioyl)benzamide
C15H13N3O3S (315.06775880000004)
Carbamic acid, [(1R)-1-(3-bromophenyl)-2-hydroxyethyl]-, 1,1-dimethylethyl ester (9CI)
1-[(3,4-dimethoxyphenyl)sulfonyl]proline
C13H17NO6S (315.07765420000004)
4-Bromo-N,N-Bis(Trimethylsilyl)Aniline
C12H22BrNSi2 (315.04740720000007)
2-(3-chloro-2-oxo-1,3-dihydroindol-4-yl)ethyl benzoate
C17H14ClNO3 (315.06621640000003)
methyl (2Z,4Z)-5-chloro-2-(chloromethyl)-5-(4-nitrophenyl)penta-2,4-dienoate
1-Methyl ethyl 2-chloro-5-[[[(1-methylethoxy)thiooxo]methyl]amino]-benzoate
2,5-Dideoxy-adenosine 3-monophosphate
C10H14N5O5P (315.07325240000006)
(3E)-3-(2-chloro-9H-thioxanthen-9-ylidene)-N,N-dimethylpropan-1-amine
C18H18ClNS (315.08484180000005)
D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014150 - Antipsychotic Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018492 - Dopamine Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants
Furo[2,3-g]-1,2-benzisoxazole-7-carboxylicacid, 5-chloro-7,8-dihydro-3-phenyl-
5-[[2,5-Dimethyl-1-(3-pyridinyl)-1H-pyrrol-3-yl]methylene]-2-thioxo-4-thiazolidinone
9-phenyl-3,4a,5,6,7,8,8a,9-octahydro-2H-5,8-methanothiochromeno[2,3-d][1,3]thiazol-2-one
3-[[Oxo(thiophen-2-yl)methyl]amino]-2-benzofurancarboxylic acid ethyl ester
C16H13NO4S (315.05652580000003)
6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one
N,N-Bis(trimethylsilyl)-3-bromoaniline
C12H22BrNSi2 (315.04740720000007)
diethyl [(1S)-1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}ethyl]phosphonate
D000970 - Antineoplastic Agents
(3r)-3-Ethyl-N-[(4-Methylphenyl)sulfonyl]-L-Aspartic Acid
C13H17NO6S (315.07765420000004)
2-Methylcarbamoyl-3-(4-phosphonooxy-phenyl)-cyclopropanecarboxylic acid
C12H14NO7P (315.05078640000005)
3,5-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)-4-oxo-4H-chromen-7-olate
3-O-methyltricetin(1-)
The conjugate base of 3-O-methyltricetin arising from selective deprotonation of the 7-OH position; major species at pH 7.3.
3,4,5-Trihydroxy-3-methoxyflavon-7-olate
The conjugate base of 3,4,5,7-tetrahydroxy-3-methoxyflavone arising from selective deprotonation of the 7-hydroxy group; major species at pH 7.3.
3-deoxy-alpha-D-manno-2-octulosonate-8-phosphate(3-)
5-Hydroxy-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzoate
5,7-Dihydroxy-2-(4-hydroxyphenyl)-8-methoxy-4-oxochromen-3-olate
Diphosphoric acid alpha-(2-methoxy-4-amino-5-pyrimidinylmethyl) ester
C6H11N3O8P2 (315.00213859999997)
2,3,4,5-Tetrafluoro-6-(3-methoxyanilino)benzoic acid
N-(1H-benzimidazol-2-yl)-2-methylsulfonylbenzamide
C15H13N3O3S (315.06775880000004)
4-(3-methylphenyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione
4-(4-chlorophenyl)-3-(2-phenylethyl)-1H-1,2,4-triazole-5-thione
2-amino-7-methyl-4-(5-nitro-2-furanyl)-5-oxo-4H-pyrano[3,2-c]pyran-3-carbonitrile
C14H9N3O6 (315.04913339999996)
N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide
N-[5-[(4-methoxyphenyl)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide
C15H13N3O3S (315.06775880000004)
5-(2-nitrophenyl)-N-(2-thiazolyl)-2-furancarboxamide
4-(3-methylphenyl)-3-(5-propan-2-yl-3-thiophenyl)-1H-1,2,4-triazole-5-thione
N-[(3-methoxybenzoyl)oxy]-4-nitrobenzenecarboximidamide
3-(4-ethyl-5-methyl-3-thiophenyl)-4-(phenylmethyl)-1H-1,2,4-triazole-5-thione
5-Nitro-2-furancarboxylic acid (5-phenyl-1,3,4-oxadiazol-2-yl)methyl ester
C14H9N3O6 (315.04913339999996)
2-[(3-Cyano-6-cyclopropyl-4-thiophen-2-yl-2-pyridinyl)thio]acetamide
1-(2-Furanyl)-2-([1,2,4]triazolo[3,4-b][1,3]benzothiazol-1-ylthio)ethanone
4-(phenylmethyl)-3-(5-propyl-3-thiophenyl)-1H-1,2,4-triazole-5-thione
4-[(1-methyl-5-tetrazolyl)thio]-5-(1H-pyrrol-2-yl)thieno[2,3-d]pyrimidine
4-hydroxy-1-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2-dihydro-3-quinolinecarboxamide
C15H13N3O3S (315.06775880000004)
2-thiophen-2-ylethyl (Z)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enoate
C16H13NO4S (315.05652580000003)
2-Amino-3-[hydroxy-(2-hydroxy-3-propanoyloxypropoxy)phosphoryl]oxypropanoic acid
hydroxyfenbendazole
C15H13N3O3S (315.06775880000004)
A member of the class of benzimidazoles that is fenbendazole in which the hydrogen at position 4 on the phenyl ring has been replaced by a hydroxy group.
4-nitrophenyl beta-D-glucuronide
A beta-D-glucosiduronic acid having a 4-nitrophenyl substituent at the anomeric position.
isorhamnetin(1-)
A flavonoid oxoanion that is the conjugate base of isorhamnetin, arising from the deprotonation of the 7-hydroxy group; major species at pH 7.3.
8-phosphonato-3-deoxy-D-manno-oct-2-ulosonate(3-)
A carbohydrate acid anion that is a trianion arising from deprotonation of the carboxy and phospho groups of 8-phospho-3-deoxy-D-manno-oct-2-ulosonic acid; major species at pH 7.3.
(1R,2S)-VU0155041
C14H15Cl2NO3 (315.04289400000005)
(1R,2S)-VU0155041, Cis regioisomer of VU0155041, is a partial mGluR4 agonist with an EC50 of 2.35 μM.
2-TEDC
C16H13NO4S (315.05652580000003)
2-TEDC is a potent inhibitor of 5-, 12-, and 15-lipoxygenase with IC50 values of 0.09 μM, 0.013 μM and 0.5 μM, respectively. 2-TEDC can be used for the research of atheroscrelosi[1].
Flupyrimin
Flupyrimin acts as an antagonist at the insect nicotinic acetylcholine receptor (nAChR)[1].
IRES-C11
IRES-C11 is a spectfic c-MYC internal ribosome entry site (IRES) translation inhibitor. IRES-C11 blocks the interaction of a requisite c-MYC IRES trans-acting factor, heterogeneous nuclear ribonucleoprotein A1, with its IRES. IRES-C11 does not inhibits BAG-1, XIAP and p53 IRESes[1][2].
VU0119498
VU0119498 is a pan Gq mAChR M1, M3, M5 positive allosteric modulator (PAM), with EC50s of 6.04, 6.38, and 4.08 μM, respectively. VU0119498 has antidiabetic activity[1][2][3].
VU0155041
C14H15Cl2NO3 (315.04289400000005)
VU0155041 is a potent, selective positive allosteric modulator (PAM) of mGluR4, with EC50s of 798 nM and 693 nM for human and rat mGluR4, respectively. VU0155041 has potential for the research of Parkinson's disease (PD)[1].
methyl (3s)-8-bromo-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
(2s,3s,4r,5r)-2-{4,6-dihydroxyimidazo[4,5-d][1,2,3]triazin-5-yl}-6-(hydroxymethyl)oxane-3,4,5-triol
C10H13N5O7 (315.08149480000003)
1-[(2r,3r,4s,5r)-5-(1-amino-2-oxoethyl)-3,4-dihydroxyoxolan-2-yl]-4-hydroxy-2-oxopyrimidine-5-carboxylic acid
methyl 6-bromo-8-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
methyl 8-bromo-6-hydroxy-7-methoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate
2-{[(2e)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid
6-hydroxy-3-[(2r,3r,4s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-7h-imidazo[4,5-d][1,2,3]triazin-4-one
C10H13N5O7 (315.08149480000003)
[2-imino-5-(4-methoxyphenyl)-3-methyl-1h-imidazol-4-yl]sulfanesulfonic acid
4-bromo-n-(5-carbamimidamidopentyl)-1h-pyrrole-2-carboxamide
2-{[(2e)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-4-hydroxybenzoic acid
3,5-dioxa-11-azahexacyclo[9.9.2.0²,⁶.0⁸,²¹.0¹⁴,²².0¹⁵,²⁰]docosa-1,6,8(21),9,14(22),15(20),16,18-octaene-12,13-dione
4-(dimethylarsoryl)-n-(2-sulfoethyl)butanimidic acid
(2r,3r,4s,5s,6r)-2-{4,6-dihydroxyimidazo[4,5-d][1,2,3]triazin-7-yl}-6-(hydroxymethyl)oxane-3,4,5-triol
C10H13N5O7 (315.08149480000003)